Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02362997 · OUTCOME

Progression-free Survival After ASCT

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion of participants
Interval / dispersion
90% Confidence Interval
Time frame
18 Months

What was measured

Proportion of patients alive and disease-free 18 months from autologous stem cell transplantation (ASCT). Progression criteria are per Lugano 2014 criteria. All patients receiving any amount of protocol treatment. Patients who have progressed or lost to follow-up prior to 18 months are counted as failures; only patients followed and progression-free for at least 18 months are counted as successes.

Groups in this outcome

Diffuse Large B Cell Lymphoma

Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

Classical Hodgkin Lymphoma

Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

Peripheral T Cell Lymphoma

Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Diffuse Large B Cell Lymphoma31
Classical Hodgkin Lymphoma30
Peripheral T Cell Lymphoma21

Reported measurements

Source class 1
Values in proportion of participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Diffuse Large B Cell Lymphoma0.58Not reported0.420.73Not reported
Classical Hodgkin Lymphoma0.77Not reported0.610.89Not reported
Peripheral T Cell Lymphoma0.62Not reported0.420.79Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.42
        upper Limit
        0.73
        value
        0.58
      2. group Id
        OG001
        lower Limit
        0.61
        upper Limit
        0.89
        value
        0.77
      3. group Id
        OG002
        lower Limit
        0.42
        upper Limit
        0.79
        value
        0.62
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    2. group Id
      OG001
      value
      30
    3. group Id
      OG002
      value
      21
    units
    Participants
description
Proportion of patients alive and disease-free 18 months from autologous stem cell transplantation (ASCT). Progression criteria are per Lugano 2014 criteria. All patients receiving any amount of protocol treatment. Patients who have progressed or lost to follow-up prior to 18 months are counted as failures; only patients followed and progression-free for at least 18 months are counted as successes.
dispersion Type
90% Confidence Interval
groups
  1. description
    Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody
    id
    OG000
    title
    Diffuse Large B Cell Lymphoma
  2. description
    Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody
    id
    OG001
    title
    Classical Hodgkin Lymphoma
  3. description
    Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody
    id
    OG002
    title
    Peripheral T Cell Lymphoma
param Type
NUMBER
reporting Status
POSTED
time Frame
18 Months
title
Progression-free Survival After ASCT
type
PRIMARY
unit Of Measure
proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice